NCT05956821 2025-12-08
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
University of Miami
Phase 1/2 Recruiting
Clinical Trials
5 trialsNCT01884740 2022-08-09
Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22
Weill Medical College of Cornell University
Phase 1/2 Terminated
NCT01238237 2017-02-01
Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA
Northwell Health
Phase 1 Completed
NCT01044225 2012-03-22
Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma
Universitair Ziekenhuis Brussel
Phase 2 Terminated
NCT00311857 2006-09-08
Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT)
Heidelberg University
Phase 1/2 Unknown